Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC102 versus oral prednisolone for idiopathic sudden sensorineural hearing loss
2021-004323-33Phase 2Active
- Sponsor
- AudioCure Pharma GmbH
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic sudden sensorineural hearing loss (ISSNHL) comparing AC102 intratympanic single dose with Oral prednisolone comparator (2 arms). Primary endpoint: Mean change in absolute hearing thresholds from baseline to Day 28. Started Dec 2021; status: active.
02
Drugs
AC102prednisolone
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on 2021-004323-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004323-33.